» Articles » PMID: 29251543

The Transpulmonary Ratio of Endothelin 1 is Elevated in Patients with Preserved Left Ventricular Ejection Fraction and Combined Pre- and Post-capillary Pulmonary Hypertension

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2017 Dec 19
PMID 29251543
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension complicating left heart disease (PH-LHD) is associated with increased morbidity and mortality, especially in patients who develop combined pre- and post-capillary PH (Cpc-PH). Mechanisms underlying PH-LHD are incompletely understood, particularly for individuals with preserved left ventricular ejection fraction (LVEF). We hypothesized that transpulmonary concentrations of biomarkers representing signaling pathways with known effects on the pulmonary circulation could provide insight into the molecular etiology of PH-LHD in patients with preserved LVEF. Blood samples were collected from the pulmonary artery (PA) and wedge positions of outpatients with normal LVEF referred for right heart catheterization. Hemodynamic tracings were reviewed to classify patients as "no PH" (n = 23) or "PH-LHD" (n = 22). A biomarker's transpulmonary ratio (TPR) was calculated as the quotient of wedge and PA concentrations. The TPR of endothelin 1 (ET-1) was elevated in Cpc-PH (n = 10) compared to no PH or isolated post-capillary PH (Ipc-PH, n = 12); cAMP and cGMP TPRs were not different among groups. Higher ET-1 TPR in Cpc-PH was due to increased wedge ET-1 concentration. Pulmonary vascular resistance (PVR) strongly correlated with wedge ET-1 exclusively in Cpc-PH patients. In patients with normal LVEF and Cpc-PH, ET-1 TPR is higher, due to elevated wedge ET-1, compared to those without PH or with Ipc-PH. Strong correlation between PVR and wedge ET-1, observed only in the Cpc-PH group, may suggest increased pulmonary vascular responsiveness to ET-1 in these patients. These findings implicate elevated pulmonary ET-1 as a marker of, and a potential contributor to, development of Cpc-PH in this population.

Citing Articles

Investigation of pulmonary artery and circulating endothelin-1 expression in dogs with pulmonary hypertension secondary to myxomatous mitral valve disease.

Tangmahakul N, Rungsipipat A, Surachetpong S Vet World. 2024; 17(9):2144-2151.

PMID: 39507783 PMC: 11536742. DOI: 10.14202/vetworld.2024.2144-2151.


Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report.

Monahan K, Kammer M, Ru Su Y, Iams W, Grogan E, Maldonado F BMC Pulm Med. 2024; 24(1):460.

PMID: 39294582 PMC: 11409683. DOI: 10.1186/s12890-024-03288-z.


Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.

Jheng J, Bai Y, Noda K, Huot J, Cook T, Fisher A Circulation. 2024; 150(11):867-883.

PMID: 38804138 PMC: 11384544. DOI: 10.1161/CIRCULATIONAHA.124.068624.


Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction.

Aradhyula V, Vyas R, Dube P, Haller S, Gupta R, Maddipati K Am J Physiol Heart Circ Physiol. 2024; 326(6):H1498-H1514.

PMID: 38639739 PMC: 11380948. DOI: 10.1152/ajpheart.00068.2024.


Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF.

Agrawal V, Kropski J, Gokey J, Kobeck E, Murphy M, Murray K Circ Res. 2023; 133(11):885-898.

PMID: 37929582 PMC: 10655859. DOI: 10.1161/CIRCRESAHA.123.323119.


References
1.
Hulsmann M, Stanek B, Frey B, Sturm B, Putz D, Kos T . Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 1998; 32(6):1695-700. DOI: 10.1016/s0735-1097(98)00437-9. View

2.
Van Beneden R, Gurne O, Selvais P, Ahn S, Robert A, Ketelslegers J . Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail. 2004; 10(6):490-5. DOI: 10.1016/j.cardfail.2004.04.001. View

3.
Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

4.
Califf R, Adams K, McKenna W, Gheorghiade M, Uretsky B, McNulty S . A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134(1):44-54. DOI: 10.1016/s0002-8703(97)70105-4. View

5.
McMurray J, Ray S, Abdullah I, Dargie H, Morton J . Plasma endothelin in chronic heart failure. Circulation. 1992; 85(4):1374-9. DOI: 10.1161/01.cir.85.4.1374. View